The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.0M data for 1.3M Compounds and 9.6K Targets. Of those, 1.5M data for 695K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Advanced Search

10 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Optimization of mTOR Inhibitors Using Property-Based Drug Design and Free-Wilson Analysis for Improved In Vivo Efficacy.EBI
Takeda California
Recent advances in PI3K/PKB/mTOR inhibitors as new anticancer agents.EBI
University of Calabria
Research progress of mTOR inhibitors.EBI
Jilin University
Contemporary mTOR inhibitor scaffolds to diseases breakdown: A patent review (2015-2021).EBI
University of Hradec Kralove
Molecular design of dual inhibitors of PI3K and potential molecular target of cancer for its treatment: A review.EBI
Bioland Laboratory (Guangzhou Regenerative Medicine and Health - Guangdong Laboratory)
Preclinical Development of PQR514, a Highly Potent PI3K Inhibitor Bearing a Difluoromethyl-Pyrimidine Moiety.EBI
University of Basel
CZ415, a Highly Selective mTOR Inhibitor Showing in Vivo Efficacy in a Collagen Induced Arthritis Model.EBI
Cellzome
Impact of Minor Structural Modifications on Properties of a Series of mTOR Inhibitors.EBI
Nestl�
A Conformational Restriction Strategy for the Identification of a Highly Selective Pyrimido-pyrrolo-oxazine mTOR Inhibitor.EBI
University of Basel
Design of Small Molecule Autophagy Modulators: A Promising Druggable Strategy.EBI
China Pharmaceutical University